Mapping the binding of GluN2B-selective N-methyl-D-aspartate receptor negative allosteric modulators

Molecular Pharmacology

Volumn 82, Issue 2, 2012, Pages 344-359

  Burger, Pieter B ^a   Yuan, Hongjie ^b   Karakas, Erkan ^c   Geballe, Matthew ^a   Furukawa, Hiro ^c   Liotta, Dennis C ^a   Snyder, James P ^a   Traynelis, Stephen F ^b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELIPRODIL; GLUN2B SUBUNIT; IFENPRODIL; LIGAND; RADIPRODIL; RECEPTOR SUBUNIT; TRAXOPRODIL; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; HUMAN; HYDROGEN BOND; MOLECULAR DYNAMICS; MUTATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SIMULATION; STEREOCHEMISTRY;

ALLOSTERIC REGULATION; ANIMALS; FEMALE; LIGANDS; MICE; MOLECULAR DYNAMICS SIMULATION; PIPERIDINES; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; XENOPUS LAEVIS;

EID: 84863885062     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.078568     Document Type: Article

References (62)

1. Akazawa C, Shigemoto R, Bessho Y, Nakanishi S, and Mizuno N (1994) Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats. J Comp Neurol 347:150-160.
2. Auffinger P, Hays FA, Westhof E, and Ho PS (2004) Halogen bonds in biological molecules. Proc Natl Acad Sci USA 101:16789-16794.
3. Avenet P, Léonardon J, Besnard F, Graham D, Frost J, Depoortere H, Langer SZ, and Scatton B (1996) Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytes. Eur J Pharmacol 296:209-213.
4. Barta-Szalai G, Borza I, Bozó E, Kiss C, Agai B, Proszenyák A, Keseru GM, Gere A, Kolok S, Galgóczy K, et al. (2004) Oxamides as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett 14:3953-3956.
5. Bowers KJ, Dror RO, and Shaw DE (2006) The midpoint method for parallelization of particle simulations. J Chem Phys 124:184109.
6. Butler TW, Blake JF, Bordner J, Butler P, Chenard BL, Collins MA, DeCosta D, Ducat MJ, Eisenhard ME, Menniti FS, et al. (1998) (3R,4S)-3-[4-(4- fluorophenyl)-4-hydroxypiperidin-1-yl]chroman-4,7-diol: a conformationally restricted analogue of the NR2B subtype-selective NMDA antagonist (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)- 1-propanol. J Med Chem 41:1172-1184.
7. Carter C, Benavides J, Legendre P, Vincent JD, Noel F, Thuret F, Lloyd KG, Arbilla S, Zivkovic B, and MacKenzie ET (1988) Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties. J Pharmacol Exp Ther 247:1222-1232.
8. Clark T, Hennemann M, Murray JS, and Politzer P (2007) Halogen bonding: the sigma-hole. Proceedings of "Modeling interactions in biomolecules II", Prague, September 5th-9th, 2005. J Mol Model 13:291-296.
9. Chenard BL, Bordner J, Butler TW, Chambers LK, Collins MA, De Costa DL, Ducat MF, Dumont ML, Fox CB, and Mena EE (1995) (1S,2S)-1-(4-hydroxyphenyl)-2- (4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. J Med Chem 38:3138-3145.
10. Chenard BL and Menniti FS (1999) Antagonists selective for NMDA receptors containing the NR2B subunit. Curr Pharm Des 5:381-404.
11. Chenard BL, Shalaby IA, Koe BK, Ronau RT, Butler TW, Prochniak MA, Schmidt AW, and Fox CB (1991) Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds. J Med Chem 34:3085-3090.
12. Citri A and Malenka RC (2008) Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology 33:18-41.
13. Coyle JT, Tsai G, and Goff D (2003) Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann NY Acad Sci 1003:318-327.
14. Edgar RC (2004) MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics 5:113.
15. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, and Pedersen LG (1995) A smooth particle mesh Ewald method. J Chem Phys 103:8577.
16. Farina AN, Blain KY, Maruo T, Kwiatkowski W, Choe S, and Nakagawa T (2011) Separation of domain contacts is required or heterotetrameric assembly of functional NMDA receptors. J Neurosci 31:3565-3579.
17. Fischer G, Mutel V, Trube G, Malherbe P, Kew JN, Mohacsi E, Heitz MP, and Kemp JA (1997) Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J Pharmacol Exp Ther 283:1285-1292.
18. Gallagher MJ, Huang H, Pritchett DB, and Lynch DR (1996) Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor. J Biol Chem 271:9603-9611.
19. Gielen M, Siegler Retchless B, Mony L, Johnson JW, and Paoletti P (2009) Mechanism of differential control of NMDA receptor activity by NR2 subunits. Nature 459:703-707.
20. Gill R, Alanine A, Bourson A, Buttelmann B, Fischer G, Heitz MP, Kew JN, Levet- Trafit B, Lorez HP, Malherbe P, et al. (2002) Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl- benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther 302:940-948.
21. Gotti B, Duverger D, Bertin J, Carter C, Dupont R, Frost J, Gaudilliere B, MacKenzie ET, Rousseau J, and Scatton B (1988) Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia. J Pharmacol Exp Ther 247:1211-1221.
22. Hallett PJ and Standaert DG (2004) Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther 102:155-174.
23. Hansen KB, Furukawa H, and Traynelis SF (2010a) Control of assembly and function of glutamate receptors by the amino-terminal domain. Mol Pharmacol 78:535-549.
24. Hansen KB, Mullasseril P, Dawit S, Kurtkaya NL, Yuan H, Vance KM, Orr AG, Kvist T, Ogden KK, Le P, et al. (2010b) Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists. J Pharmacol Exp Ther 333:650-662.
25. Hardingham GE and Bading H (2010) Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 11:682-696.
26. Hashimoto K and London ED (1995) Interactions of erythro-ifenprodil, threoifenprodil, erythro-iodoifenprodil, and eliprodil with subtypes of sigma receptors. Eur J Pharmacol 273:307-310.
27. Humphrey W, Dalke A, and Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14:33-38.
28. Imai YN, Inoue Y, Nakanishi I, and Kitaura K (2008) Cl-pi interactions in proteinligand complexes. Protein Sci 17:1129-1137.
29. Karakas E, Simorowski N, and Furukawa H (2009) Structure of the zinc-bound amino-terminal domain of the NMDA receptor NR2B subunit. EMBO J 28:3910-3920.
30. Karakas E, Simorowski N, and Furukawa H (2011) Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors. Nature 475:249-253.
31. Kew JN, Trube G, and Kemp JA (1996) A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. J Physiol 497:761-772.
32. + channels by ifenprodil. Neuropsychopharmacology 31:516-524.
33. Koller M and Urwyler S (2010) Novel N-methyl-D-aspartate receptor antagonists: a review of compounds patented since 2006. Expert Opin Ther Pat 20:1683-1702.
34. Kumar J, Schuck P, and Mayer ML (2011) Structure and assembly mechanism for heteromeric kainate receptors. Neuron 71:319-331.
35. Kumar J, Schuck P, Jin R, and Mayer ML (2009) The N-terminal domain of GluR6-subtype glutamate receptor ion channels. Nat Struct mol Biol 16:631-638.
36. Laskowski RA (2009) PDBsum new things. Nucleic Acids Res 37:D355-D359.
37. Low CM, Lyuboslavsky P, French A, Le P, Wyatte K, Thiel WH, Marchan EM, Igarashi K, Kashiwagi K, Gernert K, et al. (2003) Molecular determinants of proton-sensitive N-methyl-D-aspartate receptor gating. Mol Pharmacol 63:1212-1222.
38. Marinelli L, Cosconati S, Steinbrecher T, Limongelli V, Bertamino A, Novellino E, and Case DA (2007) Homology modeling of NR2B modulatory domain of NMDA receptor and analysis of ifenprodil binding. ChemMedChem 2:1498-1510.
39. Masuko T, Kashiwagi K, Kuno T, Nguyen ND, Pahk AJ, Fukuchi J, Igarashi K, and Williams K (1999) A regulatory domain (R1-R2) in the amino terminus of the N-methyl-D-aspartate receptor: effects of spermine, protons, and ifenprodil, and structural similarity to bacterial leucine/isoleucine/valine binding protein. Mol Pharmacol 55:957-969.
40. Matter H, Nazaré M, Güssregen S, Will DW, Schreuder H, Bauer A, Urmann M, Ritter K, Wagner M, and Wehner V (2009) Evidence for C-Cl/C-Br. . . pi interactions as an important contribution to protein-ligand binding affinity. Angew Chem Int Ed Engl 48:2911-2916.
41. McCauley JA, Theberge CR, Romano JJ, Billings SB, Anderson KD, Claremon DA, Freidinger RM, Bednar RA, Mosser SD, Gaul SL, et al. (2004) NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem 47:2089-2096.
42. Mony L, Kew JN, Gunthorpe MJ, and Paoletti P (2009a) Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol 157:1301-1317.
43. Mony L, Krzaczkowski L, Leonetti M, Le Goff A, Alarcon K, Neyton J, Bertrand HO, Acher F, and Paoletti P (2009b) Structural basis of NR2B-selective antagonist recognition by N-methyl-D-aspartate receptors. Mol Pharmacol 75:60-74.
44. Monyer H, Burnashev N, Laurie DJ, Sakmann B, and Seeburg PH (1994) Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12:529-540.
45. Mosley CA, Acker TM, Hansen KB, Mullasseril P, Andersen KT, Le P, Vellano KM, Bräuner-Osborne H, Liotta DC, and Traynelis SF (2010) Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-methyl- D-aspartate receptor antagonists. J Med Chem 53:5476-5490.
46. Mosley CA, Myers SJ, Murray EE, Santangelo R, Tahirovic YA, Kurtkaya N, Mullasseril P, Yuan H, Lyuboslavsky P, Le P, et al. (2009) Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors. Bioorg Med Chem 17:6463-6480.
47. Mott DD, Doherty JJ, Zhang S, Washburn MS, Fendley MJ, Lyuboslavsky P, Traynelis SF, and Dingledine R (1998) Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nature Neurosci 1:659-667.
48. Nagy J, Boros A, Dezso P, Kolok S, and Fodor L (2003) Inducible expression and pharmacology of recombinant NMDA receptors, composed of rat NR1a/NR2B subunits. Neurochem Int 43:19-29.
49. Perin-Dureau F, Rachline J, Neyton J, and Paoletti P (2002) Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors. J Neurosci 22:5955-5965.
50. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, and Landen JW (2008) An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 28:631-637.
51. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ, and Memantine Study Group (2003) Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348:1333-1341.
52. Roberts E, Eargle J, Wright D, and Luthey-Schulten Z (2006) MultiSeq: unifying sequence and structure data for evolutionary analysis. BMC Bioinformatics 7:382.
53. Sali A and Overington JP (1994) Derivation of rules for comparative protein modeling from a database of protein structure alignments. Protein Sci 3:1582-1596.
54. Sobolevsky AI, Rosconi MP, and Gouaux E (2009) X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature 462:745-756.
55. Tahirovic YA, Geballe M, Gruszecka-Kowalik E, Myers SJ, Lyuboslavsky P, Le P, French A, Irier H, Choi WB, Easterling K, et al. (2008) Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists. J Med Chem 51:5506-5521.
56. Tamiz AP, Whittemore ER, Schelkun RM, Yuen PW, Woodward RM, Cai SX, Weber E, and Keana JF (1998) N-(2-(4-hydroxyphenyl)ethyl)-4-chlorocinnamide: a novel antagonist at the 1A/2B NMDA receptor subtype. Bioorg Med Chem Lett 8:199-200.
57. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, and Dingledine R (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62:405-496.
58. Williams K (1993) Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 44:851-859.
59. Wright JL, Gregory TF, Kesten SR, Boxer PA, Serpa KA, Meltzer LT, Wise LD, Espitia SA, Konkoy CS, Whittemore ER, et al. (2000) Espitia SA, Konkoy CS, Whittemore ER, Woodward RM. Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalkynyl)-4- benzylpiperidines. J Med Chem 43:3408-3419.
60. Wu LJ and Zhuo M (2009) Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain. Neurotherapeutics 6:693-702.
61. Yuan H, Hansen KB, Vance KM, Ogden KK, and Traynelis SF (2009) Control of NMDA receptor function by the NR2 subunit amino-terminal domain. J Neurosci 29:12045-12058.
62. Zhao H, Berger AJ, Brown PH, Kumar J, Balbo A, May CA, Casillas E Jr, Laue TM, Patterson GH, Mayer ML, et al. (2012) Analysis of high-affinity assembly for AMPA receptor amino-terminal domains. J Gen Physiol 139:371-388.